UK – Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cance

Bayer’s Nubeqa (darolutamide) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The final draft guidance from NICE specifically recommends Nubeqa tablets in combination with androgen deprivation therapy (ADT) and docetaxel.

The decision follows the Medicines and Healthcare products Regulatory Agency’s approval of the combination in November last year under Project Orbit, an international programme to speed up the approval process of promising cancer drugs.

Bayer and NHS England have since had a commercial agreement to enable clinicians to arrange early access. The latest decision by NICE now allows additional eligible patients with mHSPC in England and Wales to receive the medication…